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ABSTRACT 
Colorectal cancer is the most common malignancy of the gastrointestinal tract with very high mortality. One of 
the most distinguishing features for the establishment of an epithelial-mesenchymal transition phenotype is the 
alteration of mesenchymal markers expression and structural adhesion proteins. We evaluated the significance of 
vimentin and fibronectin gene expression in relation to invasion and metastasis in CRC patients. Tissue specimens 
were collected consecutively from forty-five colorectal carcinoma patients during surgeries. Tissues were divided 
into two separate parts for pathological and molecular assays. In order to histological staging, tissue sections were 
prepared from formalin-fixed paraffin-embedded blocks and stained with Hematoxylin and Eosin. To quantify 
gene expression, specimens were dissected and homogenized. Moreover, SW480, SW48, SW948, Caco-2, HT-29 
and LS174T as human colon cancer cell lines were obtained and cultured, then molecular analyzing was per-
formed. As results the expression of VIM gene increased in SW480, SW48 and SW948 while it decreased in Caco-
2, HT-29 and LS174T. Moreover, FN was up-regulated in Caco-2, HT-29 and SW948, while it was down-regu-
lated in SW480, SW48 and LS174T. In tissues, vimentin and fibronectin expression significantly increased in 
stromal cells, whereas vimentin decreased in colonic epithelial cells and fibronectin had no significant change. 
Vimentin and fibronectin expression were changed in tumor tissues. It was found an association between vimentin 
expression with age and tumor size; over-expression in older age and decreasing in larger tumor size. Furthermore, 
fibronectin over-expression is correlated to older age and high tumor stages; up-regulation with increasing age and 
high tumor stages. 
 
Keywords: colorectal cancer, fibronectin, vimentin, qReal-Time PCR  
EXCLI Journal 2017;16:1009-1017 – ISSN 1611-2156 
Received: May 21, 2017, accepted: June 19, 2017, published: July 10, 2017 
 
 
1010 
INTRODUCTION 
It is well demonstrated that colorectal can-
cer (CRC) is one of the highly aggressive ma-
lignant tumors. CRC is the third cancer fol-
lowing lung and breast cancers in men and the 
second cancer in women worldwide 
(Armaghany et al., 2012). It is also a cancer 
with very high mortality, the course of the dis-
ease results in death in about one of two CRC 
patients. Over 1.2 million new CRC cases, ap-
proximately 800,000 deaths are recorded an-
nually (Jemal et al., 2011; Sun et al., 2016). 
Inherited familial CRC syndromes include 
Familial Adenomatous Polyposis (FAP) and 
Lynch Syndrome (Hereditary Non-Polyposis 
Colorectal Cancer [HNPCC]). The study of 
CRC syndromes has greatly assisted under-
standing of the molecular pathogenesis under-
lying sporadic CRC. Lynch syndrome (3-5 % 
of colorectal cancer), an autosomal dominant 
inherited disorder, is a disease in which path-
ogenesis is influenced by environmental ex-
posures, genetic and epigenetic alterations 
(Sinicrope et al., 2016). Some risk factors in-
clude lifestyle, dietary factors, side-effects of 
medical interventions, older age, family his-
tory and inherited genetic disorders (Lin, 
2009). Colorectal cancer is genetically caused 
by accumulated mutations in multiple genes 
that regulate cell growth and differentiation.  
Mutations in DNA mismatch repair (MMR) 
genes lead to profound genetic instability in-
cluding chromosomal instability (CIN) and 
microsatellite instability (MSI) (Buza et al., 
2016). Tumor development risk is increased 
through one of the most complex cellular 
events as multi-step cascading process in-
volving infinite proliferation, invasion and 
immigration (Huang et al., 2016). Recent in-
vestigations have focused on the epithelial-
mesenchymal transition (EMT) in cancer in-
vasion and metastasis (Toiyama et al., 2013). 
These researches on the molecular genomic 
targets and biomarkers underpinning EMT 
regulation hold tremendous potential in iden-
tifying the subset of patients that are at highest 
risk of developing metastasis in CRC. 
Several factors and genes are associated 
with the process of tumor angiogenesis, inva-
sion, growth and metastasis in CRC. One of 
the most distinguishing features for the estab-
lishment of an EMT phenotype is up-regu-
lated expression of mesenchymal markers and 
down-regulated expression of structural adhe-
sion proteins (Micalizzi and Ford, 2009). Vi-
mentin gene (VIM) is a mesenchymal marker 
encodes 466 amino acids polypeptide 
(53 kDa), highly conserved protein belongs to 
type III intermediate filament family (Satelli 
and Li, 2011). From studies and investigation, 
it is evident that vimentin is a multifunctional 
protein and its ability to interact with a large 
number of proteins makes it a potential regu-
lator of several different physiological func-
tions (Satelli and Li, 2011). This protein is re-
sponsible for maintaining cell shape, integrity 
of the cytoplasm, stabilizing cytoskeletal in-
teractions and involving in immune response 
(Ogrodnik et al., 2014). It functions as an or-
ganizer of a number of critical proteins in-
volved in attachment, migration, and cell sig-
naling. Vimentin expresses during embryonic 
development and predominantly in the primi-
tive streak stage, while its expression is lim-
ited to connective tissue mesenchymal cells, 
CNS and muscles in adult (Satelli and Li, 
2011).  
Fibronectin (FN) is an important extracel-
lular matrix (ECM) glycoprotein (~440 kDa) 
with several alternatively spliced variants (Ou 
et al., 2013). FN plays an important role in 
cell adhesion, migration and is involved in 
critical processes including embryogenesis, 
wound healing, blood coagulation, host de-
fense and metastasis. FN has also been impli-
cated in cancer growth and development. 
Therefore, this study was established due to 
our assumption that vimentin and fibronectin 
biomarkers may play roles in the CRC patho-
logical process. To determine whether the 
gene expression of fibroblastic markers (VIM 
and FN) have changed in CRC tissue com-
pared to normal colonic tissue, the level of 
mRNA for vimentin and fibronectin genes 
was measured. Consequently, we evaluated 
the significance of vimentin and fibronectin 
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gene expression in relation to invasion and 
metastasis in CRC patients. 
 
METHODS AND MATERIALS 
Cell lines and culture  
The human colon carcinoma cell lines 
SW480 (stage Duckes B, grade IV), SW48 
(stage Duckes C, grade X), SW948 (stage 
Duckes C, grade III), Caco-2 derived from 
large intestine carcinoma (stage X, grade II), 
HT-29 (stage Duckes C, grade I) and LS174T 
(stage Duckes B, grade X) were obtained 
from the cellular bank department of Pasteur 
Institute (Tehran, Iran). The CRC cell lines 
were maintained and cultured in Dulbecco’s 
modified Eagle’s medium (Invitrogen Corp.), 
supplemented with 10 % fetal bovine serum 
(FBS) at 37 °C under 5 % CO2. The validity 
of cell lines was routinely monitored by ana-
lyzing a series of genetic and epigenetic spe-
cific markers for each cell line. 
 
Subjects and patients  
In this experimental study, sample size 
and power for patient and normal group were 
calculated forty-five and twenty specimens, 
respectively (95 % confidence level and 5 % 
confidence interval). Forty five fresh frozen 
samples (N=45) collected consecutively from 
Tumor bank of Iran Cancer Institute of Iran, 
Imam Khomeini Hospital Complex (Tehran, 
Iran). Informed written consent was obtained 
from patients and all procedures were per-
formed according to the guidelines of scien-
tific research ethical committee of Tehran 
University of medical science.  
 
Histology and tissue collecting 
Tissue specimens were divided into two 
separate parts for pathological and molecular 
assays. To quantify gene expression, speci-
mens were dissected and stored immediately 
in -80 °C to inhibit ribonuclease enzyme and 
avoid RNA degradation. 
In order to histological staging, tissue sec-
tions were prepared from formalin-fixed par-
affin-embedded (FFPE) blocks and stained 
with Hematoxylin and Eosin (H&E). Finally, 
tissues were classified by anatomic pathol-
ogist team.  
 
RNA isolation and cDNA synthesis 
Tissue specimens (5 mg) were thawed and 
homogenized. Total RNA was extracted using 
High Pure RNA isolation kit (Roche, Ger-
many). Last, the light absorbance at 260, 280 
and 230 nm was measured using Nano-pho-
tometer 2000c (Thermo Science, USA). The 
RNA samples with optimum A260/A280 ra-
tio and A260/A230 ratio equal or more than 
1.7 were selected to synthesize complemen-
tary DNA. 
Reverse transcription reaction was per-
formed using RevertAid First Strand cDNA 
Synthesis Kit (Thermo Scientific, Lithuania). 
Reaction volume was 20 µL including; total 
RNA (1 μg≈11 µL), RevertAid RT 200 U/µL 
(1 μL), RiboLock RNase Inhibitor 20 U/µL 
(1 μL), Random Hexamer primer (1 μL), 
dNTP Mix 10 mM (2 μL) and Reaction 
Buffer 5x (4 μL). Then, samples were incu-
bated for 10 min at 25 °C, 60 min at 42 °C 
and 5 min at 75 °C. 
 
Primer set design 
Vimentin and fibronectin genes as fibro-
blastic markers were selected as target and 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene was carefully chosen as inter-
nal reference gene. Genes sequence were at-
tained, primers set were designed by Primer3 
software. Finally, oligonucleotide sequences 
were compared and aligned with human 
whole genome and transcriptom to avoid sec-
ondary structure. Oligonucleotide sequences 
are shown in Table 1. 
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Table 1: Oligonucleotide sequences and amplification fragment size 
Oligo name Sequence (5′→3′) Length Amplicon 
(bp) 
Accession 
Number 
GAPDH-F 
GAPDH-R 
5-GGGCCATCCACAGTCTTC-3  
5-GAAGGCTGGGGCTCATTTG-3 
18 
19 
255 NM_002046 
 
VIM-F 
VIM-R 
5-GGCTCAGATTCAGGAACAGC-3 
5-AGCCTCAGAGAGGTCAGCAA-3 
20 
20 
166 NM_003380 
 
FN-F 
FN-R 
5-CCAGGCAGTACAATGTGGGT-3 
5-TGGAATAGAGCTCCCAGGCT-3  
20 
20 
161 NM_212482 
 
 
 
 
Quantitative Real-Time PCR analysis 
Real-Time PCR assay based on free dye 
(SYBR Green-I) was carried out. All reac-
tions were performed by Rotor-Gene Q appa-
ratus (Qiagen, USA). Total volume for PCR 
reaction was 25 μl and including: 12.5 μl of 
SYBR Green-I PCR Master Mix 2x (TaKaRa, 
Japan), 1 μl of forward and reverse oligonu-
cleotide (0.4 μM), 5 μl of cDNA template 
(60 ng/μl) and ddH2O (5.5 μl). Real-Time 
PCR programme was 30 sec at 95 °C (Taq en-
zyme activation), following by 5 sec at 95 °C 
and 20 sec at 60 °C for 40 repeats and melting 
curve analysis ramping from 65 °C to 95 °C 
and rinsing 1 °C per each detection. 
Amplification efficiency for target and in-
ternal reference genes was validated using 2-
fold dilution series of cDNA template as 400, 
200, 100, 50, 25 ng. Standard curve was 
drawn by plotting the logarithmic input 
cDNA concentration versus mean Threshold 
Cycle (CT) and the slope was determined. 
PCR efficiency was calculated using formula; 
E %= [(10–(1/slope))-1] x 100. Expression 
level of target genes was calculated using 
comparative threshold cycle formula. The rel-
ative gene expression ratio (R) was calculated 
based on efficiency (E) and cross point (CP) 
of tumor tissues versus normal colon tissues 
using Pfaffl formula (Pfaffl, 2001). 
 
 
	
Statistical analysis 
The statistical procedures were included 
Mean ratio (M), Standard Deviation (SD), 
Confidence Intervals (95 % CI), Standard Er-
ror of Mean (SEM), Mann–Whitney assay 
and Kruskal-Wallis test. Mean values and as-
sociations between discrete variables were as-
sessed using the ANOVA and the Chi-square 
(χ2) tests, respectively. The Kaplan–Meier 
method was used to estimate tumor recur-
rence or death from CRC. Significance level 
was set at P value <0.05. All mathematical 
analyses were performed using statistical 
package for the social sciences software 
(SPSS Inc. v. 22). 
 
RESULT 
Demographic data analysis 
All CRC patients had no chemotherapy 
and were in stage I (n=12), stage II (n=18), 
stage III (n=7), stage IV (n=3) and stage X 
(n=5). Tumor tissue stages were categorized 
based on the Union for International Cancer 
Control (UICC) TNM classification system. 
The mean tumors’ size was 4.70±2.53 cm. 
The primary site of samples were included ce-
cum (n=10), rectum (n=16), Sigmoid Colon 
(n=8), Rectosigmoid (n=4), Ascending (n=3), 
Descending (n=3) and Transverse (n=1). The 
mean age of the patients was 55±15 years old 
(range 16-79), with 22 women and 23 men 
(Table 2). 
 
 
Ratioൌ
ઢେ୮	୲ୟ୰୥ୣ୲	ሺୡ୭୬୲୰୭୪	୫ୣୟ୬ି	ୱୟ୫୮୪ୣ	୫ୣୟ୬ሻ
ሺ୉	୲ୟ୰୥ୣ୲	୥ୣ୬ୣሻ																																																																																									
	 ୼େ୮	୰ୣ୤.୧୬ୢୣ୶ሺୡ୭୬୲୰୭୪	୫ୣୟ୬ିୱୟ୫୮୪ୣ	୫ୣୟ୬ሻሺ୉	୰ୣ୤ୣ୰ୣ୬ୡୣ	୥ୣ୬ୣሻ																																																																																																								
 
EXCLI Journal 2017;16:1009-1017 – ISSN 1611-2156 
Received: May 21, 2017, accepted: June 19, 2017, published: July 10, 2017 
 
 
1013 
Table 2: Demographic table including patient’s age, gender, tumor size and tumor stage 
 Gender Age 
y/o 
Primary 
site 
(colon  
region) 
Tumor 
range 
Tumor Size 
(cm) 
Tu-
mor 
Grade 
Lym-
phatic 
Inva-
sion 
Vascu-
lar 
Inva-
sion 
Multi-
ple 
Pri-
mary 
Gene 
expression 
fold 
M F 
Patient 
(n=45) 
23 22 16-78 
(55±15) 
6  Cecum 
16 Rec-
tum 
8 Sigmoid 
Colon 
4 Recto-
sigmoid 
11 other 
region 
2.0-11.0 
(4.70±2.53) 
 
I-X 24  Yes 
20  No 
4  Un-
known 
23  Yes 
19  No 
3  un-
known 
23 Yes 
19  No 
3  un-
known 
- 
VM 
up-regu-
lated 
(N=18) 
10 8 30-78 
(54±12) 
3  Cecum 
8 Rectum 
2 Sigmoid 
Colon 
3 Recto-
sigmoid 
2 other re-
gion 
2.5-11.0 
(5.03±2.66) 
I-III 8    Yes 
10  No 
0  Un-
known 
9 Yes 
9  No 
0 Un-
known 
0    Yes 
15  No 
3 Un-
known 
2.90±0.31 
VM 
down-
regulated 
(N=27) 
16 11 16-79 
(55±17) 
5  Cecum 
10 Rec-
tum 
7 Sigmoid 
Colon 
3 Recto-
sigmoid 
2 other re-
gion 
2.0-11.0 
(4.48±2.47) 
III-X 8   Yes 
14  No 
5  Un-
known 
8  Yes 
14  No 
5 Un-
known 
8    Yes 
14  No 
5 Un-
known 
0.04±0.00 
FN 
up-regu-
lated 
(N=12) 
4 8 28-78 
(55±15) 
6  Cecum 
2 Rectum 
1 Sigmoid 
Colon 
1 Recto-
sigmoid 
2 other re-
gion 
2.0-7.0 
(3.70±1.55) 
I-II 5  Yes 
7  No 
0  Un-
known 
5  Yes 
6  No 
1 Un-
known 
0  Yes 
9  No 
3 Un-
known 
124.49±14.17 
FN 
down-
regulated 
(N=33) 
21 12 16-76 
(55±15) 
7  Cecum 
11 Rec-
tum 
7 Sigmoid 
Colon 
4 Recto-
sigmoid 
4 other re-
gion 
2.0-11.0 
(4.90±2.49) 
II-X 13  Yes 
15  No 
5  Un-
known 
13  Yes 
15  No 
5 Un-
known 
2    Yes 
28  No 
3 Un-
known 
0.71±0.16 
 
 
Real-Time RT-PCR validation 
The slope of standard curves for VIM, FN 
and GAPDH genes were determined -3.39,  
-3.47 and -3.31, respectively (Figure 1). PCR 
efficiency (E) was calculated 97 % for VIM, 
94 % for FN and 100 % for GAPDH gene. 
Melting curve analysis showed the specific 
amplicon for VIM, FN and GAPDH melted at 
86.2 °C, 89.3 °C and 85.5 °C, respectively 
(Figure 2). The results of melting curves were 
confirmed by gel electrophorese analysis of 
PCR product. 
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Figure 1: Standard curves for VIM, FN and GAPDH. Mean threshold cycle (X-axis) versus log cDNA 
concentration (Y-axis). Slopes, Y-intercept and determination coefficient for interest genes; vimentin (y= 
-3.39x + 35.28, R² = 1.00), fibronectin (y= -3.47x + 39.50, R² = 0.99) and GAPDH (y= -3.31x + 27.97, 
R² = 1.00). 
 
 
 
Figure 2: Melting curve analysis: GAPDH, VIM 
and FN were melted at 85.5 °C (A), 86.2 °C (B), 
89.3 °C (C), respectively. 
 
 
VIM and FN expression in CRC cell lines 
Quantitative analysis showed that the ex-
pression of VIM gene increased in SW480 
(5.10±1.37), SW48 (2.66±0.74), SW948 
(1.71±0.29), while it decreased in Caco-2 
(0.13±0.02), HT-29 (0.28±0.08) and LS174T 
(0.11±0.00) (Figure 3).  
FN exhibited different expression pattern 
compared to VIM expression. It was up-regu-
lated in Caco-2 (15.7±1.33), HT-29 
(2.04±0.41) and SW948 (2.23±0.36) cell 
lines, while it was down-regulated in SW480 
(0.06±0.00), SW48 (0.49±0.09) and LS174T 
(0.04±0.00).  
 
 
Figure 3: VIM and FN expression in CRC cell 
lines; based on pathology, morphology and cell 
behavior 
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Data analysis showed that VIM had mod-
erate gene expression profile in normal co-
lonic tissue (mCT=25.84±1.01), while this 
represents a complex pattern in CRC tissues 
(Table 3). Quantitative Real-Time PCR re-
vealed that VIM gene expression significantly 
increased about 3-fold (P value˂0.001) in 
stromal cells and decreased approximately 
25-fold (P value˂0.001) in colonic epithelial 
cells of CRC tissues. VIM expression ratio for 
stromal cells and colonic epithelial cells was 
calculated 2.90±0.31 and 0.04±0.00, respec-
tively (Figure 4).  
Fibronectin has low gene expression pat-
tern in normal colonic tissue (mCT=32.54± 
1.36). Quantitative results showed that FN 
gene expression increased approximately two 
logarithm fold in stromal cells, while had no 
significant change in colonic epithelial cells. 
FN expression ratio in stromal cells of CRC 
tissues was calculated 124.49±14.17 (P 
value˂0.001) and in colonic epithelium was 
0.71±0.16 (P value˃0.05) (Figure 4, Table 3). 
 
Figure 4: VIM and FN expression in CRC tissues; 
based on morphology, pathology, tumor behavior. 
CONCLUSION 
Colorectal cancer is the most common malig-
nancy of the gastrointestinal tract that begins 
with transformation of normal epithelial cells 
to an adenoma, proceeding to in situ carci-
noma, and eventually to invasive and meta-
static tumor. Although, it is one of the well-
studied cancers in recent years, however, the 
pathogenesis and molecular mechanism of 
CRC is not completely understood yet. It was 
thought that the key role of CRC involved in 
genetic alterations. Genetic and epigenetic 
mutations are most common factors in CRC 
and are the driving force of tumorgenesis 
(Armaghany et al., 2012). Growing evidence 
suggests that some biomarkers play an im-
portant role in CRC development, progression 
and metastasis (Brenner and Rennert, 2005; 
Ou et al., 2013; Satelli and Li, 2011; Toiyama 
et al., 2013). Vimentin and fibronectin genes 
are responsible for maintaining cell shape, cy-
toplasm integrity, stabilizing cytoskeletal in-
teractions, cell signaling, migration and cell 
adhesion (Micalizzi and Ford, 2009; Ogrod-
nik et al., 2014). These genes evaluated in var-
ious epithelial cancers including prostate can-
cer, gastrointestinal tumors, CNS tumors, 
breast cancer, malignant melanoma, lung can-
cer and other cancers (Satelli and Li, 2011). 
Many studies and investigations have re-
ported that in majority of the cancers, vi-
mentin and fibronectin gene expression are al-
tered and revealed an association between 
their expression and cancer aggressiveness 
(Mclnroy and Maatta, 2007; Ngan et al., 
2007; Sethi et al., 2010; Wei et al., 2008; 
Williams et al., 2009). 
 
Table 3: VIM and FN expression profile in CRC cell lines (Median±IQR) 
Target genes 
CRC cell lines (Mean±SD) 
SW480 HT-29 LS174T SW48 Caco-2 SW948 P-value 
VIM- Mean CT 21.90±0.80 28.77±0.66 29.69±0.64 22.75±0.44 30.99±1.02 29.77±0.93 
<0.001 
VIM expression  5.10±1.37 0.28±0.08 4.5±0.91 2.66±0.74 0.13±0.02 1.71±0.29 
FN- Mean CT 32.35±1.13 29.90±0.79 32.23±0.39 29.20±0.36 26.89±0.53 33.38±0.79 
<0.001 
FN expression  0.06±0.00 2.04±0.41 1.64±0.13 0.49±0.09 15.7±1.33 2.23±0.36 
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Essentially, expression of vimentin is 
mainly associated with metastatic phenotype 
and poor prognosis of the disease outcome. In 
the present study, fresh frozen CRC tissues 
were studied simultaneously with seven colo-
rectal cell lines. The objective using cell line 
was the classification based on aggressive-
ness degree in cell lines and determination the 
expression profile of target genes in CRC cell 
lines compared to normal cell line. Our results 
showed that mRNA level of VIM increased in 
SW480, SW48 and SW948, while it de-
creased in Caco-2, HT-29 and LS174T. Fi-
bronectin expression, moreover, had different 
pattern and behavior relative to VIM profile. 
It was up-regulated in Caco-2, HT-29 and 
SW948 cell lines, while it was down-regu-
lated in SW480, SW48 and LS174T. 
Quantitative data analysis showed that vi-
mentin had complex pattern in CRC tissues. 
VIM expression is up-regulated in stromal 
cells and down-regulated in colonic epithelial 
cells of CRC tissues. It was found no statisti-
cal association between VIM gene expression 
with age, gender and tumor size (p˃0.05). 
However, the mRNA level of VIM gene was 
increased in low tumor grade (I-III) and was 
decreased (silenced or suppressed) in high tu-
mor grade (III-X). Wei-Dong Chen and his 
colleagues using Immunohistochemical assay 
of vimentin expression in the human colon 
showed the absence of VIM protein in the co-
lonic epithelial cells in both normal colonic 
crypts and in colon cancers. They showed vi-
mentin gene is expressed in stromal cells 
within both normal and cancerous colon tis-
sue (Chen et al., 2005). 
One of the most crucial steps in the tumor 
cell metastatic cascade is the acquisition of in-
vasive capabilities, including destroying cell–
cell junctions, degrading the cell matrix, and 
activating pathways that control the cytoskel-
etal dynamics of cancer cells. Fibronectin is 
an important Extracellular matrix (ECM) gly-
coprotein that plays an important role in cell 
adhesion, migration, cancer growth and de-
velopment. Based on our finding, it is found 
that the FN gene expression is up-regulated in 
stromal cells of CRC tissue, while no signifi-
cant change was observed in colonic epithe-
lial cells. Data analysis revealed that fibron-
ectin expression has no statistical differences 
with age, gender and tumor size (p˃0.05). But 
fibronectin mRNA level was dependent to tu-
mor stages; up-regulation with low tumor 
stages (I-II) and decreased in high tumor stage 
(II-X). Recent studies on fibronectin expres-
sion reported that fibronectin expression lev-
els are significantly higher in malignant tu-
mors than benign tumors and normal tissues 
(Ou et al., 2013; Rybak et al., 2007; Saito et 
al., 2008). Juanjuan Ou and his colleagues re-
ported that fibronectin level was substantially 
higher in CRC compared to normal colon tis-
sue. They also showed that this protein level 
was significantly higher in CRC tissues. 
Many important features need to establish 
EMT phenotype. One of the most distinguish-
ing features is alteration in expression of 
structural adhesion proteins (down-regula-
tion) and mesenchymal markers such as vi-
mentin and fibronectin (up-regulation). 
Though all findings indicate a future signifi-
cance of vimentin and fibronectin genes for 
different malignancies with clinical rele-
vance, however, more research will be neces-
sary to particularly assess the major function 
of these genes in the process of EMT and tu-
morgenesis in colorectal carcinoma.  
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